CancerNCT07628556
Antidiabetic Medications and Risk of Cancer
An observational study of Cancer, run by University of Pecs at 1 site in Hungary.
Trial summary
A retrospective analysis was conducted based on data of the National Health Insurance Fund in Hungary. Overall cancer risk and site-specific cancer risks were analysed in a target trial emulation design when comparing all available antidiabetic therapies to MET and monotherapies and primary combination therapies… Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- Metformin, sulphonylurea and DPP-4 inhibitor
- How many people
- 74,799 participants
- Where
- 1 siteHungary
- Study dates
- 15 Mar 2025to 30 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The source population consisted of all individuals aged ≥19 years on 1 January 2016 who had no inpatient or outpatient care for malignant disease between 2009 and 2015 and no antidiabetic drug dispensing between 2011-2015. The primary study population included individuals from this source population who dispensed any antidiabetic medication between 2016 and 2022.
Who may be able to join
- Type 2 diabetes mellitus
- Antidiabetic medication initiators
Who cannot join
- Antidiabetic prescription in the previous 5 years
- Recent pancreatectomy (previous or subsequent 90 days after inclusion)
Trial locations and contacts
1 site in 1 country.
About this study
A retrospective analysis was conducted based on data of the National Health Insurance Fund in Hungary. Overall cancer risk and site-specific cancer risks were analysed in a target trial emulation design when comparing all available antidiabetic therapies to MET and monotherapies and primary combination therapies against each other. The model used in the analysis was corrected for age, gender, co-morbidities, selected cardiovascular medications and inpatient and outpatient visits.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MetforminDrug
Metformin monotherapy
sulphonylureaDrug
SU monotherapy
DPP-4 inhibitorDrug
DPP-4 inhibitor monotherapy
GLP-1 Receptor AgonistsDrug
GLP-1 Receptor Agonist monotherapy
SGLT-2 inhibitorDrug
SGLT-2 inhibitor monotherapy
insulinDrug
Insulin monotherapy
MET + SUDrug
MET + SU combination
MET + DPP-4 inhibitorDrug
MET + DPP-4 inhibitor combination
MET + GLP-1RADrug
MET + GLP-1RA combination
MET + SGLT2iDrug
MET + SGLT2i combination
MET + INSDrug
MET + insulin combination
| Study group | Role | What they receive |
|---|---|---|
| Type 2 diabetes mellitus | Not described Receives: Drug: Metformin; Drug: sulphonylurea; Drug: DPP-4 inhibitor; Drug: GLP-1 Receptor Agonists; Drug: SGLT-2 inhibitor; Drug: insulin; Drug: MET + SU; Drug: MET + DPP-4 inhibitor; Drug: MET + GLP-1RA; Drug: MET + SGLT2i; Drug: MET + INS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall cancer risk
Measured: 2016-2022
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2026
- Study start15 Mar 2025
- Primary completion30 Dec 2025
- Study completion30 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 74,799 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Pecs
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, István Wittmann, University of Pecs
- Investigators
- György Rokszin, M.D., Ph.D., Study chair
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07628556
- Sponsor's protocol ID
- PTE Antidiab_cc_2026
- Status last verified
- May 2026
- First submitted
- 31 May 2026
- Last updated
- 5 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- Individual data sharing
- No: Because of data security reasons, individual-level data are not available to the researchers
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Antidiabetic Medications and Risk of Cancer
- ClinicalTrials.gov ID
- NCT07628556
- Acronym / sponsor ID
- PTE Antidiab_cc_2026
- Conditions
- Cancer
- Keywords
- Antidiabetic agents, risk of cancer, Type 2 diabetes mellitus
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 74,799 participants (actual)
- Lead sponsor
- University of PecsUniversity, hospital or other
- Study start
- 15 Mar 2025 (actual)
- Primary completion
- 30 Dec 2025 (actual)
- Study completion
- 30 Dec 2025 (actual)
- First posted
- 5 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A retrospective analysis was conducted based on data of the National Health Insurance Fund in Hungary. Overall cancer risk and site-specific cancer risks were analysed in a target trial emulation design when comparing all available antidiabetic therapies to MET and monotherapies and primary combination therapies against each other. The model used in the analysis was corrected for age, gender, co-morbidities, selected cardiovascular medications and inpatient and outpatient visits.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Type 2 diabetes mellitus | – | Drug: Metformin, Drug: sulphonylurea, Drug: DPP-4 inhibitor, Drug: GLP-1 Receptor Agonists, Drug: SGLT-2 inhibitor, Drug: insulin, Drug: MET + SU, Drug: MET + DPP-4 inhibitor, Drug: MET + GLP-1RA, Drug: MET + SGLT2i, Drug: MET + INS |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The source population consisted of all individuals aged ≥19 years on 1 January 2016 who had no inpatient or outpatient care for malignant disease between 2009 and 2015 and no antidiabetic drug dispensing between 2011-2015. The primary study population included individuals from this source population who dispensed any antidiabetic medication between 2016 and 2022.
Key inclusion criteria (2 listed)
- Type 2 diabetes mellitus
- Antidiabetic medication initiators
Key exclusion criteria (2 listed)
- Antidiabetic prescription in the previous 5 years
- Recent pancreatectomy (previous or subsequent 90 days after inclusion)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MetforminMetformin monotherapy | Drug | Type 2 diabetes mellitus |
| sulphonylureaSU monotherapy | Drug | Type 2 diabetes mellitus |
| DPP-4 inhibitorDPP-4 inhibitor monotherapy | Drug | Type 2 diabetes mellitus |
| GLP-1 Receptor AgonistsGLP-1 Receptor Agonist monotherapy | Drug | Type 2 diabetes mellitus |
| SGLT-2 inhibitorSGLT-2 inhibitor monotherapy | Drug | Type 2 diabetes mellitus |
| insulinInsulin monotherapy | Drug | Type 2 diabetes mellitus |
| MET + SUMET + SU combination | Drug | Type 2 diabetes mellitus |
| MET + DPP-4 inhibitorMET + DPP-4 inhibitor combination | Drug | Type 2 diabetes mellitus |
| MET + GLP-1RAMET + GLP-1RA combination | Drug | Type 2 diabetes mellitus |
| MET + SGLT2iMET + SGLT2i combination | Drug | Type 2 diabetes mellitus |
| MET + INSMET + insulin combination | Drug | Type 2 diabetes mellitus |
Primary outcome
Overall cancer risk
Time frame: 2016-2022
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2026.
- Individual participant dataSharing planned: No. Because of data security reasons, individual-level data are not available to the researchers
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
György Rokszin, M.D., Ph.D. study chair
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by University of Pecs at 1 site in Hungary.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hungary. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall cancer risk (time frame: 2016-2022). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2026.